巴瑞替尼治疗中重度斑秃的临床研究
Clinical study of baricitinib in treating moderate to severe alopecia areata
丁韵卜 1毕凌波 1王超凡 1杜怡梅 1卢昌佩 1苏彤 2赵敏 1林雪雯 1孙蔚凌 1范卫新1
作者信息
- 1. 南京医科大学第一附属医院皮肤科,江苏 南京 210029
- 2. 南京医科大学附属江宁医院皮肤科,江苏 南京 211100
- 折叠
摘要
目的:观察巴瑞替尼治疗中重度斑秃患者的疗效及安全性.方法:接受＞6个月传统治疗但无明显毛发再生的中重度斑秃患者[脱发严重程度评估工具(SALT)评分≥25],予口服巴瑞替尼2 mg/d(若用药12周后SALT评分较用药前降低≤20％,增加剂量至4 mg/d),用药后4周、12周及24周门诊随访,进行SALT评分、研究者整体评估(IGA)评分及安全性评价.结果:43例患者均完成了 24周的随访,其中13例用药后12周增加剂量至4 mg/d.用药24周后,72.1％的患者头皮毛发覆盖面积＞80％,51.2％的患者IGA评分较基线改善≥2分.所有患者均未发生严重不良事件.结论:巴瑞替尼治疗中重度斑秃具有较好的临床疗效和安全性.
Abstract
Objective:To evaluate the efficacy and safety of baricitinib in the treatment of moderate to severe alopecia areata.Methods:Patients with moderate to severe alopecia areata(SALT≥25),whose responses to conventional treatment had failed,received baricitinib(2 mg/d,oral)(if the SALT score decreased by ≤20％after 12 weeks of medication compared to the base-line,the dosage increased to 4 mg/d).Patients were followed up at 4,12,and 24 weeks after treatment.The hair growth and adverse reactions at these time points were observed.Results:Forty-three patients completed a 24-week treatment,and the dose increased to 4 mg/d at week 12 in 13 patients.After 24 weeks of treatment,72.1％of the patients had hair covering more than 80％of the scalp,and 51.2％of the patients had an increase of ≥2 points in Investigator's Global Assessment(IGA)score from the baseline.No serious adverse reactions occurred.Conclusion:Baricitinib has good clinical efficacy and safety in the treatment of moderate to severe alopecia areata.
关键词
斑秃/巴瑞替尼/Janus激酶Key words
alopecia areata/baricitinib/Janus kinase引用本文复制引用
出版年
2025
NETL
NSTL
万方数据